friday, September 22, 2023
| Agenda | |
|---|---|
| Session 1: Cellular Therapy in Solid Tumors | |
| T Cell Receptor Engineered Immune Cells Efficiency is Dictated by Modulation of Tumor Microenvironment Richard Koya, MD, PhD | |
| Understanding and overcoming T-cell therapy challenges for brain tumors Giedre Krenciute, PhD | |
| Janet Rowley Keynote Lecture | |
| Insights into mechanisms of CAR T-cell resistance and toxicity through single cell analysis Michael Green, PhD | |
| Session 2: Cellular Therapy in Non-Malignant Diseases | |
| Immune special forces: Virus-specific T cells to combat infections in immunocompromised patients Michael Keller, MD | |
| Engineering Tregs against anti-drug antibody formation Moanaro Biswas, PhD | |
| Jonas Memorial Keynote Lecture | |
| Jonas Memorial Lecture- Mechanisms driving CAR T cells Marcela Maus, MD, PhD | |
| Session 3: Overcoming Resistance and Relapse to Cellular Therapy | |
| Challenges with anti-BCMA CAR T-Cell Therapy for Multiple Myeloma Samir Parekh, MD | |
| Memory reprogramming to enhance CAR T cell persistence Evan Weber, PhD | |
| Session 4: Lightening Talks | |
| Targeting PRDM1/PRDM1-mediated pathways to enhance CAR T cell efficacy against DLBCL Sidney Wang | |
| Drugging the BCL-2 family to increase CART cell effector responses Nada Aboelella, PhD | |
| Ex vivo PI3K Inhibition Enhances CAR T Cell Therapy for DLBCL Lishi Xie, PhD | |
| Session 5: Novel Cellular Therapies- From Bench to Bedside | |
| CAR T-cells for T-cell Malignancies Rayne Rouce, MD | |
| CART for T Cell Malignancies John DiPersio, MD, PhD |